Arbutus Biopharma Corporation
ABUS
$5.15
-$0.04-0.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.01M | 179.13M | 1.05M | 529.00K | 10.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.01M | 179.13M | 1.05M | 529.00K | 10.74M |
| Cost of Revenue | 2.90M | 4.12M | 5.01M | 5.78M | 5.50M |
| Gross Profit | -1.88M | 175.01M | -3.96M | -5.25M | 5.24M |
| SG&A Expenses | 3.87M | 5.89M | 3.69M | 3.04M | 3.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.77M | 10.01M | 8.70M | 8.82M | 8.83M |
| Operating Income | -5.75M | 169.12M | -7.64M | -8.29M | 1.91M |
| Income Before Tax | -5.14M | 169.70M | -3.76M | -7.74M | 2.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.14M | 169.70M | -3.76M | -7.74M | 2.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.14M | 169.70M | -3.76M | -7.74M | 2.52M |
| EBIT | -5.75M | 169.12M | -7.64M | -8.29M | 1.91M |
| EBITDA | -5.74M | 169.13M | -7.63M | -8.28M | 1.92M |
| EPS Basic | -0.03 | 0.88 | -0.02 | -0.04 | 0.01 |
| Normalized Basic EPS | -0.02 | 0.55 | -0.02 | -0.02 | 0.01 |
| EPS Diluted | -0.03 | 0.87 | -0.02 | -0.04 | 0.01 |
| Normalized Diluted EPS | -0.02 | 0.54 | -0.02 | -0.02 | 0.01 |
| Average Basic Shares Outstanding | 197.47M | 193.77M | 192.35M | 191.78M | 191.55M |
| Average Diluted Shares Outstanding | 197.47M | 195.21M | 192.35M | 191.78M | 192.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |